Start Submission

Reading: Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative dise...

Download

A- A+
Alt. Display

Research Article

Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases

Authors:

Aida M. Mohammedeid ,

Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK
X close

Vera Lukashchuk,

Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK
X close

Ke Ning

Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK
X close

Abstract

Therapeutic targets for neurodegenerative conditions are constantly emerging. Diseases such as amyotrophic lateral sclerosis and Huntington׳s disease are multifactorial and involve dysfunction of various cellular pathways. Protein aggregate formation is one of the crucial pathological signs of cellular dysfunction, and is characteristic of many neurodegenerative conditions. Proteins recruited to these aggregates are thought to play a role in formation of the pathogenic inclusions. This review aims at exploring the current evidence for protein aggregation and the role for Arfaptin2, as a candidate factor contributing to the formation of aggresomes and a potential therapeutic target in motor neuron disease.

Focal points

•   Bedside

Understanding the multifactorial nature of the pathogenesis of neurodegenerative diseases will contribute to the research into the therapeutic targets of the disease, allowing more factors to be discovered in patients affected by the debilitating disorders of the nervous system.

•   Benchside

Collaborative efforts in investigating the causes and pathways of neurodegeneration are likely to increase the chance of discovering novel therapy approaches that may be utilised in more than one type of neurodegenerative disorders.

•   Industry

The application of the novel therapeutic target such as Arfaptin, and other proteins associated with protein aggregates, to the development of therapy approaches may open new avenues in drug discovery for neurodegenerative diseases.

•   Community

Diseases of central nervous system bear a great impact on the quality of life of the patients and their carers. Promoting the awareness through communicating the current state of the research provides a form of a mental support to those affected by these conditions.

•   Regulatory agencies

The need for funding the research into the basic understanding of the mechanisms involved in the pathogenesis of the neurodegenerative conditions must not be overlooked. The research into the cellular defects provides with invaluable findings about the healthy and diseased cell functioning.

 

How to Cite: Mohammedeid, A.M., Lukashchuk, V. & Ning, K., (2014). Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. New Horizons in Translational Medicine. 2(1), pp.12–15. DOI: http://doi.org/10.1016/j.nhtm.2014.08.004
11
Views
2
Downloads
Published on 27 Aug 2014.
Peer Reviewed

Downloads

  • PDF (EN)